Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | BUY | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy | Buy | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Rising Three Methods | 1D | Current | |||
Completed Patterns | |||||
Tri-Star Bearish | 15 | 1 | Apr 23, 2024 07:00 | ||
Tri-Star Bullish | 30 | 4 | Apr 22, 2024 07:30 | ||
Three Outside Down | 1M | 5 | Nov 23 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 169.54 | 168.00 | 171.89 | 4,082,844 | +0.98% | USD | |||
London | 168.64 | 161.68 | 178.68 | 0 | +0.91% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,803.98 | 2,803.98 | 3,050.00 | 0 | 0.00% | MXN | |||
Milan | 157.60 | 0.00 | 0.00 | 0 | 0.00% | EUR | |||
TradeGate | 158.98 | 157.90 | 158.98 | 95 | +0.67% | EUR | |||
Frankfurt | 158.12 | 158.10 | 159.62 | 0 | +0.79% | EUR | |||
B3 | 54.25 | 53.29 | 55.60 | 39 | -0.28% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Rolls-Royce Holdings | 420.90 | 423.80 | 416.60 | +3.70 | +0.89% | 1.79M | 08:42:11 | ||
IAG | 177.95 | 178.30 | 176.65 | +2.00 | +1.14% | 1.48M | 08:41:16 | ||
Barclays | 190.96 | 193.82 | 190.84 | -1.28 | -0.67% | 3.31M | 08:41:29 | ||
HSBC | 664.80 | 668.40 | 664.00 | -2.90 | -0.43% | 2.75M | 08:41:55 | ||
Lloyds Banking | 50.42 | 50.86 | 49.62 | -0.92 | -1.79% | 30.76M | 08:42:03 | ||
Vodafone Group PLC | 68.940 | 69.820 | 68.878 | -0.680 | -0.98% | 1.93M | 08:41:52 | ||
BP | 528.40 | 531.10 | 528.40 | +5.30 | +1.01% | 2.08M | 08:42:03 | ||
British American Tobacco | 2,362.0 | 2,373.0 | 2,362.0 | +2.0 | +0.08% | 150.34K | 08:41:54 | ||
Legal & General | 251.30 | 254.20 | 251.20 | -1.80 | -0.71% | 1.29M | 08:41:53 | ||
Avacta Group | 44.01 | 45.00 | 44.00 | -0.49 | -1.10% | 201.90K | 08:41:59 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review